| Patient | Howard Hughes |
|---|---|
| Date of birth | 1984-12-24 |
| Identifiers | MRN HR-ML006-SYN; SSN (made up) 000-06-5571 |
| Document date | 2026-06-08 |
| Author | Anselm Garrity-Moyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week review: OCD treatment, buprenorphine, pain and the audiogram. [S]
Mr. Hughes returns four weeks after starting buprenorphine and sertraline. Withdrawal settled on the second day of buprenorphine, and on 8 mg twice daily he has no cravings and has taken no other opioid; his bowels are a little slow, and he is drinking more water. He has had four exposure sessions: he now touches door handles and his desk without washing at once, and he lets himself wash for two minutes rather than ten. Washing and checking take about three hours a day. His assistant has attended one session. He has had no side effects from sertraline; no one from the clinic called two weeks after he started it. Physical therapy twice weekly has eased his shoulder. He eats two meals a day. He could not bring himself to use the clinic bathroom today, so no urine test has been done since intake. The audiogram was done this morning. [S]
| Element | Detail |
|---|---|
| Buprenorphine | 8 mg twice daily; no cravings; no other opioid use |
| Rituals | About three hours a day; Y-BOCS 24 |
| Sertraline | 50 mg for four weeks; no side effects |
| Pain | PEG 5.7 |
| Audiogram | Bilateral high-frequency sensorineural loss |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; sleeping six hours |
| Gastrointestinal | Positive | Mild constipation |
| Musculoskeletal | Positive | Shoulder pain better; chest wall and back pain persist |
| Psychiatric | Positive | Contamination fears somewhat less; no thoughts of suicide or of harming anyone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a day | One or two tablets every 6 hours as needed, no more than 8 a day | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-05-04 | active | S |
| Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day | First-day induction by the written plan, no more than 16 mg | Sublingual route | 2026-05-11 to 2026-05-12 | completed | S |
| Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first | One film under the tongue twice daily | Sublingual route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped | Two tablets three times daily, no more than 3,000 mg a day | Oral route | 2026-05-11 | active | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 to 2026-07-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-08 | Body height | 191 | cm | S |
| 2026-06-08 | Body weight | 73.4 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 78 | /min | S |
| 2026-06-08 | Respiratory rate | 14 | /min | S |
| 2026-06-08 | Body temperature | 36.6 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-08 | Hearing threshold Ear - right --500 Hz | 20 | dB | 25 dB HL or better is normal hearing | Normal | S |
| 2026-06-08 | Hearing threshold Ear - left --500 Hz | 20 | dB | 25 dB HL or better is normal hearing | Normal | S |
| 2026-06-08 | Hearing threshold Ear - right --1000 Hz | 25 | dB | 25 dB HL or better is normal hearing | Normal | S |
| 2026-06-08 | Hearing threshold Ear - left --1000 Hz | 30 | dB | 25 dB HL or better is normal hearing | High | S |
| 2026-06-08 | Hearing threshold Ear - right --2000 Hz | 35 | dB | 25 dB HL or better is normal hearing | High | S |
| 2026-06-08 | Hearing threshold Ear - left --2000 Hz | 40 | dB | 25 dB HL or better is normal hearing | High | S |
| 2026-06-08 | Hearing threshold Ear - right --4000 Hz | 60 | dB | 25 dB HL or better is normal hearing | High | S |
| 2026-06-08 | Hearing threshold Ear - left --4000 Hz | 65 | dB | 25 dB HL or better is normal hearing | High | S |
| 2026-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-06-08 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 10 | {score} | S | ||
| 2026-06-08 | Mean score [PEG] | 5.7 | {score} | S |
Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 78; weight 73.4 kg, BMI 20.1 |
| Ears | Canals clear; tympanic membranes normal |
| Skin | Hands less cracked |
| Musculoskeletal | Left shoulder elevation 150 degrees |
| Psychiatric | Less tense; no sedation; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluation | resolved | confirmed | R46.81 | S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947. |
| Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screening | active | confirmed | F42.2 | S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis. |
| Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine planned | active | confirmed | F11.20 | S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis. |
| Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7 | active | confirmed | G89.21 | S — Synthetic modern diagnosis anchored to his documented injuries. |
| Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluation | resolved | confirmed | H91.93 | S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years. |
| Bilateral high-frequency sensorineural hearing loss with a notch at 4000 Hz, consistent with noise exposure from flying; hearing aids fitted | active | confirmed | H90.3 | S — Synthetic modern diagnosis made at five weeks; not a claim about his real hearing in 1947. |
| Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fears | active | confirmed | R63.4 | S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 24; about three hours a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Four of four sessions attended; home practice most days |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Deferred | The two-week tolerability check after sertraline started was not done. No harm: he had no side effects, activation or suicidal thoughts at four weeks. Corrective action: a nurse telephone call two weeks after each dose change, booked today |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | His assistant attended one session; staff still wrap objects in tissue for him |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 7, item 9 scored 0; GAD-7 10 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use; mild constipation; no sedation |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Deferred | Not collected: he could not use the clinic bathroom because of contamination fears. No sign of harm: no other prescriptions on the monitoring report, and he reports no other use. Corrective action: the test is the next step on his exposure hierarchy, with his therapist, at the ten-week visit |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 5.7 |
| Referral | Physical therapy and graded activity | Twice weekly | Completed today | Eight sessions; shoulder elevation 150 degrees |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 73.4 kg, up 1.4 kg; two meals a day |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Baseline normal; next at about six months |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Bilateral high-frequency sensorineural loss with a notch at 4000 Hz |
Goal progress:
Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse telephone call in two weeks. Ten-week review in five weeks, with hearing aid fitting that morning and the urine test as an exposure exercise. Call the clinic or 988 at any time. Next scheduled visit 2026-07-13: ten-week review: sertraline to an OCD dose, exposure therapy and his staff's part in it, hearing aids and pain. [S]